These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 8336309

  • 1. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease.
    Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C.
    J Rheumatol; 1993 May; 20(5):838-44. PubMed ID: 8336309
    [Abstract] [Full Text] [Related]

  • 2. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
    Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM.
    Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
    [Abstract] [Full Text] [Related]

  • 3. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
    Wanchu A, Suryanaryana BS, Sharma S, Sharma A, Bambery P.
    Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
    [Abstract] [Full Text] [Related]

  • 4. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease.
    Várai G, Earle L, Jimenez SA, Steiner RM, Varga J.
    J Rheumatol; 1998 Jul; 25(7):1325-9. PubMed ID: 9676764
    [Abstract] [Full Text] [Related]

  • 5. Cyclophosphamide versus placebo in scleroderma lung disease.
    Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Scleroderma Lung Study Research Group.
    N Engl J Med; 2006 Jun 22; 354(25):2655-66. PubMed ID: 16790698
    [Abstract] [Full Text] [Related]

  • 6. Serial changes in scleroderma and idiopathic interstitial lung disease.
    Colp CR, Riker J, Williams MH.
    Arch Intern Med; 1973 Oct 22; 132(4):506-15. PubMed ID: 4742404
    [No Abstract] [Full Text] [Related]

  • 7. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
    Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, Sterz MG, Chung J, FitzGerald JD, Seibold JR, Varga J, Theodore A, Wigley FM, Silver RM, Steen VD, Mayes MD, Connolly MK, Fessler BJ, Rothfield NF, Mubarak K, Molitor J, Tashkin DP, Scleroderma Lung Study Group.
    Arthritis Rheum; 2005 Feb 22; 52(2):592-600. PubMed ID: 15692967
    [Abstract] [Full Text] [Related]

  • 8. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease.
    Mittoo S, Wigley FM, Wise R, Xiao H, Hummers L.
    Arthritis Rheum; 2007 Dec 22; 56(12):4195-202. PubMed ID: 18050251
    [Abstract] [Full Text] [Related]

  • 9. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis.
    Colaci M, Sebastiani M, Giuggioli D, Manfredi A, Spagnolo P, Luppi F, Richeldi L, Ferri C.
    Scand J Rheumatol; 2010 Mar 22; 39(2):155-9. PubMed ID: 20059446
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.
    Bérezné A, Ranque B, Valeyre D, Brauner M, Allanore Y, Launay D, Le Guern V, Kahn JE, Couderc LJ, Constans J, Cohen P, Mahr A, Pagnoux C, Hachulla E, Kahan A, Cabane J, Guillevin L, Mouthon L.
    J Rheumatol; 2008 Jun 22; 35(6):1064-72. PubMed ID: 18464307
    [Abstract] [Full Text] [Related]

  • 11. Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease.
    Valentini G, Paone C, La Montagna G, Chiarolanza I, Menegozzo M, Colutta E, Ruocco L.
    Scand J Rheumatol; 2006 Jun 22; 35(1):35-8. PubMed ID: 16467039
    [Abstract] [Full Text] [Related]

  • 12. Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre.
    Beretta L, Caronni M, Raimondi M, Ponti A, Viscuso T, Origgi L, Scorza R.
    Clin Rheumatol; 2007 Feb 22; 26(2):168-72. PubMed ID: 16614793
    [Abstract] [Full Text] [Related]

  • 13. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
    Bérezné A, Valeyre D, Ranque B, Guillevin L, Mouthon L.
    Ann N Y Acad Sci; 2007 Sep 22; 1110():271-84. PubMed ID: 17911442
    [Abstract] [Full Text] [Related]

  • 14. Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations.
    Kowal-Bielecka O, Kowal K, Rojewska J, Bodzenta-Lukaszyk A, Siergiejko Z, Sierakowska M, Sierakowski S.
    Ann Rheum Dis; 2005 Sep 22; 64(9):1343-6. PubMed ID: 16100339
    [Abstract] [Full Text] [Related]

  • 15. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis.
    Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML, Fulminis A, De Luca A, Farina G, Candela M, Generini S, De Francisci A, Tirri E, Proietti M, Bombardieri S, Gabrielli A, Tonietti G, Cerinic MM.
    J Rheumatol; 2002 Apr 22; 29(4):731-6. PubMed ID: 11950014
    [Abstract] [Full Text] [Related]

  • 16. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis.
    Calguneri M, Apras S, Ozbalkan Z, Ertenli I, Kiraz S, Ozturk MA, Celik I.
    Clin Rheumatol; 2003 Oct 22; 22(4-5):289-94. PubMed ID: 14579158
    [Abstract] [Full Text] [Related]

  • 17. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis.
    Apras S, Ertenli I, Ozbalkan Z, Kiraz S, Ozturk MA, Haznedaroglu IC, Cobankara V, Pay S, Calguneri M.
    Arthritis Rheum; 2003 Aug 22; 48(8):2256-61. PubMed ID: 12905480
    [Abstract] [Full Text] [Related]

  • 18. Determinants of response to immunosuppressive therapy in idiopathic pulmonary fibrosis.
    van Oortegem K, Wallaert B, Marquette CH, Ramon P, Perez T, Lafitte JJ, Tonnel AB.
    Eur Respir J; 1994 Nov 22; 7(11):1950-7. PubMed ID: 7875264
    [Abstract] [Full Text] [Related]

  • 19. Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease.
    Kowal-Bielecka O, Distler O, Kowal K, Siergiejko Z, Chwiećko J, Sulik A, Gay RE, Łukaszyk AB, Gay S, Sierakowski S.
    Arthritis Rheum; 2003 Jun 22; 48(6):1639-46. PubMed ID: 12794832
    [Abstract] [Full Text] [Related]

  • 20. Bronchoalveolar lavage in systemic sclerosis with lung involvement: role and correlations with functional, radiological and scintigraphic parameters.
    Volpinari S, La Corte R, Bighi S, Ravenna F, Prandini N, Lo Monaco A, Trotta F.
    Rheumatol Int; 2011 Sep 22; 31(9):1183-8. PubMed ID: 20352228
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.